Metabolic syndrome, chronic kidney disease, and cardiovascular disease: A dynamic and life-threatening triad

Cardiology Research and Practice

Volumn 1, Issue 1, 2011, Pages

  Lopes, José António ^a   Raimundo, Mário ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NITRIC OXIDE; PLACEBO; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FLUID RETENTION; GLYCEMIC CONTROL; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 79959453427     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.4061/2011/747861     Document Type: Review

References (187)

1. Manson J. E., Skerrett P. J., Greenland P., VanItallie T. B., The escalating pandemics of obesity and sedentary lifestyle: a call to action for clinicians Archives of Internal Medicine 2004 164 3 249 258 (Pubitemid 38176465)
2. Weiss R., Dziura J., Burgert T. S., Tamborlane W. V., Taksali S. E., Yeckel C. W., Allen K., Lopes M., Savoye M., Morrison J., Sherwin R. S., Caprio S., Obesity and the metabolic syndrome in children and adolescents New England Journal of Medicine 2004 350 23 2362 2374 (Pubitemid 38702847)
3. Reaven G. M., Banting lecture 1988. Role of insulin resistance in human disease Diabetes 1988 37 12 1595 1607 (Pubitemid 19004941)
4. DeFronzo R. A., Ferrannini E., Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care 1991 14 3 173 194
5. Lindsay R. S., Howard B. V., Cardiovascular risk associated with the metabolic syndrome Current Diabetes Reports 2004 4 1 63 68 (Pubitemid 39359512)
6. Koh K. K., Han S. H., Quon M. J., Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions Journal of the American College of Cardiology 2005 46 11 1978 1985 (Pubitemid 41713578)
7. Alberti K. G. M. M., Zimmet P. Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation Diabetic Medicine 1998 15 7 539 553 (Pubitemid 28319935)
8. Balkau B., Charles M. A., Comment on the provisional report from the WHO consultation Diabetic Medicine 1999 16 5 442 443
9. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Journal of the American Medical Association 2001 285 19 2486 2497 (Pubitemid 32433843)
10. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 2005 112 17 2735 2752 (Pubitemid 41532612)
11. Alberti K. G. M. M., Zimmet P., Shaw J., The metabolic syndromea new worldwide definition Lancet 2005 366 9491 1059 1062 (Pubitemid 41338752)
12. Ford E. S., Giles W. H., Dietz W. H., Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey Journal of the American Medical Association 2002 287 3 356 359 (Pubitemid 34251969)
13. Ford E. S., Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S Diabetes Care 2005 28 11 2745 2749 (Pubitemid 43951170)
14. Ford E. S., Giles W. H., Mokdad A. H., Increasing prevalence of the metabolic syndrome among U.S. adults Diabetes Care 2004 27 10 2444 2449 (Pubitemid 39281399)
15. Wilson P. W. F., D'Agostino R. B., Parise H., Sullivan L., Meigs J. B., Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 2005 112 20 3066 3072 (Pubitemid 43113437)
16. de Ferranti S. D., Gauvreau K., Ludwig D. S., Neufeld E. J., Newburger J. W., Rifai N., Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey Circulation 2004 110 16 2494 2497 (Pubitemid 39407358)
17. Hanson R. L., Imperatore G., Bennett P. H., Knowler W. C., Components of the "metabolic syndrome" and incidence of type 2 diabetes Diabetes 2002 51 10 3120 3127
18. Resnick H. E., Jones K., Ruotolo G., Jain A. K., Henderson J., Lu W., Howard B. V., Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study Diabetes Care 2003 26 3 861 867 (Pubitemid 36929356)
19. Klein B. E. K., Klein R., Lee K. E., Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam Diabetes Care 2002 25 10 1790 1794 (Pubitemid 41071088)
20. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D. ST. J., Haffner S. M., Isles C., Macfarlane P. W., Packard C. J., Cobbe S. M., Shepherd J., Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 2003 108 4 414 419 (Pubitemid 36935533)
21. Sattar N., McConnachie A., Shaper A. G., Blauw G. J., Buckley B. M., de Craen A. J., Ford I., Forouhi N. G., Freeman D. J., Jukema J. W., Lennon L., Macfarlane P. W., Murphy M. B., Packard C. J., Stott D. J., Westendorp R. G., Whincup P. H., Shepherd J., Wannamethee S. G., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies Lancet 2008 371 9628 1927 1935
22. Ford E. S., Li C., Sattar N., Metabolic syndrome and incident diabetes: current state of the evidence Diabetes Care 2008 31 9 1898 1904
23. Ford E. S., Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence Diabetes Care 2005 28 7 1769 1778 (Pubitemid 40923091)
24. Galassi A., Reynolds K., He J., Metabolic syndrome and risk of cardiovascular disease: a meta-analysis American Journal of Medicine 2006 119 10 812 819 (Pubitemid 44415613)
25. Gami A. S., Witt B. J., Howard D. E., Erwin P. J., Gami L. A., Somers V. K., Montori V. M., Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies Journal of the American College of Cardiology 2007 49 4 403 414 (Pubitemid 46135879)
26. Meigs J. B., Wilson P. W. F., Fox C. S., Vasan R. S., Nathan D. M., Sullivan L. M., D'Agostino R. B., Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease Journal of Clinical Endocrinology and Metabolism 2006 91 8 2906 2912 (Pubitemid 44271734)
27. National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification American Journal of Kidney Diseases 2002 39 S1 S246
28. Culleton B. F., Larson M. G., Wilson P. W. F., Evans J. C., Parfrey P. S., Levy D., Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney International 1999 56 6 2214 2219 (Pubitemid 30004750)
29. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease American Journal of Kidney Diseases 1998 32 5 S112 S119
30. Muntner P., He J., Hamm L., Loria C., Whelton P. K., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States Journal of the American Society of Nephrology 2002 13 3 745 753 (Pubitemid 34183941)
31. Gerstein H. C., Mann J. F. E., Yi Q., Zinman B., Dinneen S. F., Hoogwerf B., Hallé J. P., Young J., Rashkow A., Joyce C., Nawaz S., Yusuf S., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals Journal of the American Medical Association 2001 286 4 421 426 (Pubitemid 32681484)
32. El Nahas A. M., Bello A. K., Chronic kidney disease: the global challenge Lancet 2005 365 9456 331 340 (Pubitemid 40139112)
33. Coresh J., Astor B. C., Greene T., Eknoyan G., Levey A. S., Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey American Journal of Kidney Diseases 2003 41 1 1 12 (Pubitemid 36043346)
34. Foley R. N., Murray A. M., Li S., Herzog C. A., McBean A. M., Eggers P. W., Collins A. J., Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999 Journal of the American Society of Nephrology 2005 16 2 489 495 (Pubitemid 41725146)
35. Mann J. F. E., Gerstein H. C., Poque J., Bosch J., Yusuf S., Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Annals of Internal Medicine 2001 134 8 629 636 (Pubitemid 32322240)
36. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization New England Journal of Medicine 2004 351 13 1296 1370
37. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N., Beige J., Brunet P., Cohen G., De Deyn P. P., Descamps-Latscha B., Herget-Rosenthal S., Hrl W., Jankowski J., Jrres A., Rodriguez M., Stegmayr B., Stenvinkel P., Wanner C., Weissinger E., Wiecek A., Zidek W., Chronic kidney disease as cause of cardiovascular morbidity and mortality Nephrology Dialysis Transplantation 2005 20 1048 1056 (Pubitemid 40862092)
38. van Biesen W., de Bacquer D., Verbeke F., Delanghe J., Lameire N., Vanholder R., The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years European Heart Journal 2007 28 4 478 483 (Pubitemid 47343557)
39. Fort J., Chronic renal failure: a cardiovascular risk factor Kidney International 2005 68 99 S25 S29
40. U.S. Renal Data System, Atlas of end-stage renal disease in the United States USRDS 2002 Annual Data Report 2002 Bethesda, Md, USA National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
41. Sarnak M. J., Coronado B. E., Greene T., Wang S. R., Kusek J. W., Beck G. J., Levey A. S., Cardiovascular disease risk factors in chronic renal insufficiency Clinical Nephrology 2002 57 5 327 335 (Pubitemid 34477469)
42. Muntner P., Coresh J., Smith J. C., Eckfeldt J., Klag M. J., Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney International 2000 58 1 293 301 (Pubitemid 30429874)
43. Bergstrm J., Inflammation, malnutrition, cardiovascular disease and mortality in end-stage renal disease Polskie Archiwum Medycyny Wewnetrznej 2000 104 4 641 643
44. Middleton R. J., Parfrey P. S., Foley R. N., Left ventricular hypertrophy in the renal patient Journal of the American Society of Nephrology 2001 12 5 1079 1084 (Pubitemid 32378350)
45. Foley R. N., Parfrey P. S., Sarnak M. J., Epidemiology of cardiovascular disease in chronic renal disease Journal of the American Society of Nephrology 1998 9 12 S16 S23
46. Foley R. N., Parfrey P. S., Cardiac disease in chronic uremia: clinical outcome and risk factors Advances in Renal Replacement Therapy 1997 4 3 234 248 (Pubitemid 27304998)
47. Harnett J. D., Foley R. N., Kent G. M., Barre P. E., Murray D., Parfrey P. S., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors Kidney International 1995 47 3 884 890
48. Parfrey P. S., Foley R. N., Harnett J. D., Kent G. M., Murray D., Barre P. E., Outcome and risk factors of ischemic heart disease in chronic uremia Kidney International 1996 49 5 1428 1434 (Pubitemid 26166417)
49. Dries D. L., Exner D. V., Domanski M. J., Greenberg B., Stevenson L. W., The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction Journal of the American College of Cardiology 2000 35 3 681 689 (Pubitemid 30167025)
50. Al Suwaidi J., Reddan D. N., Williams K., Pieper K. S., Harrington R. A., Califf R. M., Granger C. B., Ohman E. M., Holmes D. R., Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes Circulation 2002 106 8 974 980 (Pubitemid 34925333)
51. Shlipak M. G., Fried L. F., Crump C., Bleyer A. J., Manolio T. A., Tracy R. P., Furberg C. D., Psaty B. M., Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency Circulation 2003 107 1 87 92 (Pubitemid 36070938)
52. Stenvinkel P., Heimbrger O., Paultre F., Diczfalusy U., Wang T., Berglund L., Jogestrand T., Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure Kidney International 1999 55 5 1899 1911 (Pubitemid 29197978)
53. Irish A. B., Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis Metabolism 1997 46 1 36 40 (Pubitemid 27052021)
54. Kronenberg F., Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease Current Opinion in Nephrology and Hypertension 1998 7 3 271 278 (Pubitemid 28238129)
55. Festa A., D'Agostino R., Howard G., Mykknen L., Tracy R. P., Haffner S. M., Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS) Circulation 2000 102 1 42 47 (Pubitemid 30430551)
56. Pickup J. C., Mattock M. B., Chusney G. D., Burt D., NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X Diabetologia 1997 40 11 1286 1292 (Pubitemid 27469668)
57. Panichi V., Migliori M., de Pietro S., Taccola D., Blanchi A. M., Norpoth M., Giovannini L., Palla R., Tetta C., C-reactive protein as a marker of chronic inflammation in uremic patients Blood Purification 2000 18 3 183 190 (Pubitemid 30619957)
58. Mykknen L., Zaccaro D. J., O'Leary D. H., Howard G., Robbins D. C., Haffner S. M., Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects: the insulin resistance atheroselerosis study (IRAS) Stroke 1997 28 9 1710 1716 (Pubitemid 27391437)
59. Goodman W. G., Goldin J., Kuizon B. D., Yoon C., Gales B., Sider D., Wang Y., Chung J., Emerick A., Greaser L., Elashoff R. M., Salusky I. B., Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis New England Journal of Medicine 2000 342 20 1478 1483 (Pubitemid 30318271)
60. Zatz R., Dunn B. R., Meyer T. W., Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension Journal of Clinical Investigation 1986 77 6 1925 1930 (Pubitemid 16062649)
61. Cooper M. E., Pathogenesis, prevention, and treatment of diabetic nephropathy Lancet 1998 352 9123 213 219 (Pubitemid 28327814)
62. Whelton P. K., Perneger T. V., He J., Klag M. J., The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence Journal of Human Hypertension 1996 10 10 683 689 (Pubitemid 27037518)
63. Iseki K., Ikemiya Y., Kinjo K., Inoue T., Iseki C., Takishita S., Body mass index and the risk of development of end-stage renal disease in a screened cohort Kidney International 2004 65 5 1870 1876 (Pubitemid 38591038)
64. Kopple J. D., Greene T., Chumlea W. C., Hollinger D., Maroni B. J., Merrill D., Scherch L. K., Schulman G., Wang S. R., Zimmer G. S., Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study Kidney International 2000 57 4 1688 1703 (Pubitemid 30207928)
65. Manttari M., Tiula E., Alikoski T., Manninen V., Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 1995 26 4 670 675
66. Hunsicker L. G., Adler S., Caggiula A., England B. K., Greene T., Kusek J. W., Rogers N. L., Teschan P. E., Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney International 1997 51 6 1908 1919 (Pubitemid 27252762)
67. Fried L. F., Orchard T. J., Kasiske B. L., Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney International 2001 59 1 260 269 (Pubitemid 32055234)
68. Chen J., Muntner P., Hamm L. L., Jones D. W., Batuman V., Fonseca V., Whelton P. K., He J., The metabolic syndrome and chronic kidney disease in U.S. Adults Annals of Internal Medicine 2004 140 3 167 I39
69. Mykknen L., Zaccaro D. J., Wagenknecht L. E., Robbins D. C., Gabriel M., Haffner S. M., Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study Diabetes 1998 47 5 793 800 (Pubitemid 28201810)
70. Hoehner C. M., Greenlund K. J., Rith-Najarian S., Casper M. L., McClellan W. M., Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project Journal of the American Society of Nephrology 2002 13 6 1626 1634 (Pubitemid 34579251)
71. Palaniappan L., Carnethon M., Fortmann S. P., Association between microalbuminuria and the metabolic syndrome: NHANES III American Journal of Hypertension 2003 16 11 952 958 (Pubitemid 37315495)
72. Fujikawa R., Okubo M., Egusa G., Kohno N., Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study Diabetes Research and Clinical Practice 2001 53 2 99 106 (Pubitemid 32509976)
73. Zhang L., Zuo L., Wang F., Wang M., Wang S., Liu L., Wang H., Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older Mayo Clinic Proceedings 2007 82 7 822 827 (Pubitemid 47015461)
74. Kurella M., Lo J. C., Chertow G. M., Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults Journal of the American Society of Nephrology 2005 16 7 2134 2140 (Pubitemid 41716445)
75. Tanaka H., Shiohira Y., Uezu Y., Higa A., Iseki K., Metabolic syndrome and chronic kidney disease in Okinawa, Japan Kidney International 2006 69 2 369 374 (Pubitemid 43323089)
76. Rashidi A., Ghanbarian A., Azizi F., Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population Clinical Journal of the American Society of Nephrology 2007 2 5 976 983
77. Chen J., Gu D., Chen C. S., Wu X., Hamm L. L., Muntner P., Batuman V., Lee C. H., Whelton P. K., He J., Association between the metabolic syndrome and chronic kidney disease in Chinese adults Nephrology Dialysis Transplantation 2007 22 4 1100 1106 (Pubitemid 46523424)
78. Kitiyakara C., Yamwong S., Cheepudomwit S., Domrongkitchaiporn S., Unkurapinun N., Pakpeankitvatana V., Sritara P., The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort Kidney International 2007 71 7 693 700 (Pubitemid 46494568)
79. Luk A. O. Y., So W. Y., Ma R. C. W., Kong A. P. S., Ozaki R., Ng V. S. W., Yu L. W. L., Lau W. W. Y., Yang X., Chow F. C. C., Chan J. C. N., Tong P. C. Y., Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes A 5-year prospective analysis of the Hong Kong diabetes registry Diabetes Care 2008 31 12 2357 2361
80. Jang S. Y., Kim I.-H., Ju E. Y., Ahn S. J., Kim D.-K., Lee S. W., Chronic kidney disease and metabolic syndrome in a general Korean population: the Third Korea National Health and Nutrition Examination Survey (KNHANES III) Study Journal of Public Health 2010 32 4 538 546
81. Yu M., Ryu D. R., Kim S. J., Choi K. B., Kang D. H., Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey Nephrology Dialysis Transplantation 2010 25 2 469 477
82. Becker B., Kronenberg F., Kielstein J. T., Haller H., Morath C., Ritz E., Fliser D., Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study Journal of the American Society of Nephrology 2005 16 4 1091 1098 (Pubitemid 41710320)
83. Thorn L. M., Forsblom C., Fagerudd J., Thomas M. C., Pettersson-Fernholm K., Saraheimo M., Wadén J., Rnnback M., Rosengrd-Brlund M., Bjrkesten C. G. A., Taskinen M. R., Groop P. H., Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study) Diabetes Care 2005 28 8 2019 2024 (Pubitemid 41060978)
84. Kobayashi S., Maejima S., Ikeda T., Nagase M., Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis Nephrology Dialysis Transplantation 2000 15 1 65 70 (Pubitemid 30037932)
85. Bakker S. J. L., Gansevoort R. T., de Zeeuw D., Metabolic syndrome: a fata morgana? Nephrology Dialysis Transplantation 2007 22 1 15 20 (Pubitemid 46050318)
86. Chen J., Muntner P., Hamm L. L., Fonseca V., Batuman V., Whelton P. K., He J., Insulin resistance and risk of chronic kidney disease in nondiabetic US adults Journal of the American Society of Nephrology 2003 14 2 469 477 (Pubitemid 36150872)
87. Hsu C. Y., McCulloch C. E., Iribarren C., Darbinian J., Go A. S., Body mass index and risk for end-stage renal disease Annals of Internal Medicine 2006 144 1 21 28 (Pubitemid 46780716)
88. Sjoholm A., Nystrom T., Endothelial inflammation in insulin resistance Lancet 2005 365 9459 610 612 (Pubitemid 40247919)
89. Sowers J. R., Metabolic risk factors and renal disease Kidney International 2007 71 8 719 720 (Pubitemid 46624014)
90. zcan U., Cao Q., Yilmaz E., Lee A. H., Iwakoshi N. N., zdelen E., Tuncman G., Grgn C., Glimcher L. H., Hotamisligil G. S., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 2004 306 5695 457 461 (Pubitemid 39372439)
91. Kaneto H., Nakatani Y., Miyatsuka T., Kawamori D., Matsuoka T. A., Matsuhisa M., Kajimoto Y., Ichijo H., Yamasaki Y., Hori M., Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide Nature Medicine 2004 10 10 1128 1132 (Pubitemid 39424876)
92. Bridgewater D. J., Ho J., Sauro V., Matsell D. G., Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway Kidney International 2005 67 4 1308 1314 (Pubitemid 40463107)
93. Carlyle M., Jones O. B., Kuo J. J., Hall J. E., Chronic cardiovascular and renal actions of leptin: role of adrenergic activity Hypertension 2002 39 2 496 501 (Pubitemid 34165172)
94. Moreno-Manzano V., Ishikawa Y., Lucio-Cazana J., Kitamura M., Selective involvement of superoxide anion, but not downstream compounds hydrogen peroxide and peroxynitrite, in tumor necrosis factor- -induced apoptosis of rat mesangial cells Journal of Biological Chemistry 2000 275 17 12684 12691 (Pubitemid 30241419)
95. Zhou X., Yang G., Davis C. A., Doi S. Q., Hirszel P., Wingo C. S., Agarwal A., Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells Kidney International 2004 65 1 139 147 (Pubitemid 38037498)
96. Perlstein T. S., Gerhard-Herman M., Hollenberg N. K., Williams G. H., Thomas A., Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects Journal of the American Society of Nephrology 2007 18 3 944 951 (Pubitemid 46434511)
97. Balkau B., Charles M. A., Comment on the provisional report from the WHO consultation Diabetic Medicine 1999 16 5 442 443
98. Khamaisi M., Flyvbjerg A., Haramati Z., Raz G., Wexler I. D., Raz I., Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin-like growth factor 1 system in mild streptozotocin diabetes International Journal of Experimental Diabetes Research 2002 3 4 257 264 (Pubitemid 36104740)
99. Wang S., DeNichilo M., Brubaker C., Hirschberg R., Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy Kidney International 2001 60 1 96 105 (Pubitemid 32587544)
100. Lupia E., Elliot S. J., Lenz O., Zheng F., Hattori M., Striker G. E., Striker L. J., IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy Diabetes 1999 48 8 1638 1644 (Pubitemid 29356874)
101. Kambham N., Markowitz G. S., Valeri A. M., Lin J., D'Agati V. D., Obesity-related glomerulopathy: an emerging epidemic Kidney International 2001 59 4 1498 1509 (Pubitemid 32281241)
102. Cohen A. H., Massive obesity and the kidney: a morphologic and statistical study American Journal of Pathology 1975 81 1 117 127
103. Kasiske B. L., O'Donnell M. P., Keane W. F., The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury Hypertension 1992 19 1 I110 I115
104. Chagnac A., Weinstein T., Korzets A., Ramadan E., Hirsch J., Gafter U., Glomerular hemodynamics in severe obesity American Journal of PhysiologyRenal Physiology 2000 278 5 F817 F822
105. Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y., The effects of weight loss on renal function in patients with severe obesity Journal of the American Society of Nephrology 2003 14 6 1480 1486 (Pubitemid 36687049)
106. Tomaszewski M., Charchar F. J., Maric C., McClure J., Crawford L., Grzeszczak W., Sattar N., Zukowska-Szczechowska E., Dominiczak A. F., Glomerular hyperfiltration: a new marker of metabolic risk Kidney International 2007 71 8 816 821 (Pubitemid 46624026)
107. Tuttle K. R., Bruton J. L., Perusek M. C., Lancaster J. L., Kopp D. T., DeFronzo R. A., Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus New England Journal of Medicine 1991 324 23 1626 1632
108. Tuttle K. R., Puhlman M. E., Cooney S. K., Short R. A., Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes American Journal of PhysiologyRenal Physiology 2002 282 1 F103 F112
109. Maddox D. A., Alavi F. K., Santella R. N., Zawada E. T. Jr., Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction Kidney International 2002 62 1 208 219 (Pubitemid 34754064)
110. Meek R. L., Cooney S. K., Flynn S. D., Chouinard R. F., Poczatek M. H., Murphy-Ullrich J. E., Tuttle K. R., Amino acids induce indicators of response to injury in glomerular mesangial cells American Journal of PhysiologyRenal Physiology 2003 285 1 F79 F86
111. Tuttle K. R., Johnson E. C., Cooney S. K., Anderberg R. J., Johnson G E. K., Clifton D., Meek R. L., Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C Kidney International 2005 67 3 953 968 (Pubitemid 41623319)
112. Bonnefont-Rousselot D., Bastard J. P., Jaudon M. C., Delattre J., Consequences of the diabetic status on the oxidant/antioxidant balance Diabetes and Metabolism 2000 26 3 163 176 (Pubitemid 30435761)
113. Oberg B. P., McMenamin E., Lucas F. L., McMonagle E., Morrow J., Ikizler T. A., Himmelfarb J., Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease Kidney International 2004 65 3 1009 1016 (Pubitemid 38251077)
114. Nishikawa T., Araki E., Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications Antioxidants and Redox Signaling 2007 9 3 343 353 (Pubitemid 46150966)
115. Ruan X. Z., Varghese Z., Powis S. H., Moorhead J. F., Human mesangial cells express inducible macrophage scavenger receptor Kidney International 1999 56 2 440 451 (Pubitemid 29353141)
116. Ruan X. Z., Varghese Z., Moorhead J. F., Inflammation modifies lipid-mediated renal injury Nephrology Dialysis Transplantation 2003 18 1 27 32 (Pubitemid 36104475)
117. Gavras I., Gavras H., Angiotensin II as a cardiovascular risk factor Journal of Human Hypertension 2002 16 2 S2 S6
118. Chalmers L., Kaskel F. J., Bamgbola O., The role of obesity and its bioclinical correlates in the progression of chronic kidney disease Advances in Chronic Kidney Disease 2006 13 4 352 364 (Pubitemid 44512239)
119. Guichard C., Moreau R., Pessayre D., Epperson T. K., Krause K. H., NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? Biochemical Society Transactions 2008 36 5 920 929
120. Prabhakar S. S., Role of nitric oxide in diabetic nephropathy Seminars in Nephrology 2004 24 4 333 344 (Pubitemid 38900633)
121. Bakris G. L., Clinical importance of microalbuminuria in diabetes and hypertension Current Hypertension Reports 2004 6 5 352 356 (Pubitemid 39359572)
122. Garg J. P., Bakris G. L., Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease Vascular Medicine 2002 7 1 35 43 (Pubitemid 34654072)
123. Montagnani M., Ravichandran L. V., Chen H., Esposito D. L., Quon M. J., Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells Molecular Endocrinology 2002 16 8 1931 1942 (Pubitemid 34828099)
124. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M. J., Adiponectin stimulates production of nitric oxide in vascular endothelial cells Journal of Biological Chemistry 2003 278 45 45021 45026 (Pubitemid 37377262)
125. Laine H., Knuuti M. J., Ruotsalainen U., Raitakari M., Iida H., Kapanen J., Kirvel O., Haaparanta M., Yki-Jrvinen H., Nuutila P., Insulin resistance in essential hypertension is characterized by impaired insulin stimulation of blood flow in skeletal muscle Journal of Hypertension 1998 16 2 211 219 (Pubitemid 28085294)
126. Steinberg H. O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A. D., Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance Journal of Clinical Investigation 1996 97 11 2601 2610
127. Steinberg H. O., Paradisi G., Hook G., Crowder K., Cronin J., Baron A. D., Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production Diabetes 2000 49 7 1231 1238 (Pubitemid 30439100)
128. Anfossi G., Cavalot F., Massucco P., Mattiello L., Mularoni E., Hahn A., Trovati M., Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells Metabolism 1993 42 9 1081 1083 (Pubitemid 23292679)
129. Ferri C., Pittoni V., Piccoli A., Laurenti O., Cassone M. R., Bellini C., Properzi G., Valesini G., De Mattia G., Santucci A., Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo Journal of Clinical Endocrinology and Metabolism 1995 80 3 829 835
130. Marsen T. A., Schramek H., Dunn M. J., Renal actions of endothelin: linking cellular signaling pathways to kidney disease Kidney International 1994 45 2 336 344 (Pubitemid 24065064)
131. Cirillo P., Sautin Y. Y., Kanellis J., Kang D.-H., Gesualdo L., Nakagawa T., Johnson R. J., Systemic inflammation, metabolic syndrome and progressive renal disease Nephrology Dialysis Transplantation 2009 24 5 1384 1387
132. Gaby A. R., Adverse effects of dietary fructose Alternative Medicine Review 2005 10 4 294 306 (Pubitemid 41803484)
133. Elliott S. S., Keim N. L., Stern J. S., Teff K., Havel P. J., Fructose, weight gain, and the insulin resistance syndrome American Journal of Clinical Nutrition 2002 76 5 911 922 (Pubitemid 35244659)
134. Hwang I., Ho H., Hoffman B. B., Reaven G. M., Fructose-induced insulin resistance and hypertension in rats Hypertension 1987 10 5 512 516 (Pubitemid 18011228)
135. Dwyer J. T., Evans M., Stone E. J., Feldman H. A., Lytle L., Hoelscher D., Johnson C., Zive M., Yang M., Adolescents' eating patterns influence their nutrient intakes Journal of the American Dietetic Association 2001 101 7 798 802 (Pubitemid 33712958)
136. Corry D. B., Eslami P., Yamamoto K., Nyby M. D., Makino H., Tuck M. L., Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system Journal of Hypertension 2008 26 2 269 275
137. Cirillo R., Gersch M. S., Mu W., Scherer P. M., Kim K. M., Gesualdo L., Henderson G. N., Johnson R. J., Sautin Y. Y., Ketohexokinase-dependent metabolism of fructose Induces proinflammatory mediators in proximal tubular cells Journal of the American Society of Nephrology 2009 20 3 545 553
138. Roncal C. A., Mu W., Croker B., Reungjui S., Ouyang X., Tabah-Fisch I., Johnson R. J., Ejaz A. A., Effect of elevated serum uric acid on cisplatin-induced acute renal failure American Journal of PhysiologyRenal Physiology 2007 292 1 F116 F122
139. Kang D. H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., Truong L., Harris R., Johnson R. J., A role for uric acid in the progression of renal disease Journal of the American Society of Nephrology 2002 13 12 2888 2897 (Pubitemid 35386908)
140. Ridker P. M., Hennekens C. H., Buring J. E., Rifai N., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women New England Journal of Medicine 2000 342 12 836 843 (Pubitemid 30165206)
141. Soriano S., Gonzlez L., Martn-Malo A., Rodrguez M., Aljama P., Cabrera S. S., C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 35 patients Clinical Nephrology 2007 67 6 352 357 (Pubitemid 46894799)
142. Arici M., Walls J., End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney International 2001 59 2 407 414 (Pubitemid 32157905)
143. Bochud M., Nussberger J., Bovet P., Maillard M. R., Elston R. C., Paccaud F., Shamlaye C., Burnier M., Plasma aldosterone is independently associated with the metabolic syndrome Hypertension 2006 48 2 239 245 (Pubitemid 44309818)
144. Kidambi S., Kotchen J. M., Grim C. E., Raff H., Mao J., Singh R. J., Kotchen T. A., Association of adrenal steroids with hypertension and the metabolic syndrome in blacks Hypertension 2007 49 3 704 711
145. Colussi G., Catena C., Lapenna R., Nadalini E., Chiuch A., Sechi L. A., Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients Diabetes Care 2007 30 9 2349 2354 (Pubitemid 47359046)
146. Fujita T., Spotlight on renin. The renin system, salt-sensitivity and metabolic syndrome Journal of the Renin-Angiotensin-Aldosterone System 2006 7 3 181 183
147. Korantzopoulos P., Elisaf M., Milionis H. J., Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney diseaseready for prime time? Nephrology Dialysis Transplantation 2007 22 10 2768 2774 (Pubitemid 350093476)
148. Gde P., Vedel P., Larsen N., Jensen G. V. H., Parving H. H., Pedersen O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes New England Journal of Medicine 2003 348 5 383 393 (Pubitemid 36159355)
149. Schrier R. W., Estacio R. O., Esler A., Mehler P., Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney International 2002 61 3 1086 1097 (Pubitemid 34175478)
150. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C. E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., De Galan B. E., Joshi R., Travert F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes New England Journal of Medicine 2008 358 24 2560 2572 (Pubitemid 351831357)
151. Gerstein H. C., Miller M. E., Byington R. P., Effects of intensive glucose lowering in type 2 diabetes New England Journal of Medicine 2008 358 24 2545 2559 (Pubitemid 351831356)
152. Cushman W. C., Evans G. W., Byington R. P., Goff Jr. D. C., Grimm Jr. R. H., Cutler J. A., Simons-Morton D. G., Basile J. N., Corson M. A., Probstfield J. L., Katz L., Peterson K. A., Friedewald W. T., Buse J. B., Bigger J. T., Gerstein H. C., Ismail-Beigi F., Effects of intensive blood-pressure control in type 2 diabetes mellitus New England Journal of Medicine 2010 362 17 1575 1585
153. Eidemak I., Feldt-Rasmussen B., Kanstrup I. L., Nielsen S. L., Schmitz O., Strandgaard S., Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity Diabetologia 1995 38 5 565 572
154. Wing R. R., Marquez B., Behavioral aspects of weight loss in type 2 diabetes Current Diabetes Reports 2008 8 2 126 131
155. Navarro-Daz M., Serra A., Romero R., Bonet J., Bayés B., Homs M., Pérez N., Bonal J., Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up Journal of the American Society of Nephrology 2006 17 supplement 3 S213 S217
156. Heymsfield S. B., Segal K. R., Hauptman J., Lucas C. P., Boldrin M. N., Rissanen A., Wilding J. P. H., Sjstrm L., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults Archives of Internal Medicine 2000 160 9 1321 1326 (Pubitemid 30252779)
157. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., D'Armiento M., D'Andrea F., Giugliano D., Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial Journal of the American Medical Association 2004 292 12 1440 1446 (Pubitemid 39258336)
158. American Diabetes Association, Standards of medical care in diabetes 2010 Diabetes Care 2010 33 supplement 1 S11 S61
159. Casas J. P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A. D., MacAllister R. J., Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 2005 366 9502 2026 2033 (Pubitemid 41773378)
160. Schmieder R. E., Hilgers K. F., Schlaich M. P., Schmidt B. M., Renin-angiotensin system and cardiovascular risk Lancet 2007 369 9568 1208 1219 (Pubitemid 46527856)
161. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome Lancet 2005 365 9468 1415 1428 (Pubitemid 40523737)
162. Mancia G., de Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A. M., Kjeldsen S. E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R. E., Boudier H. A. J. S., Zanchetti A., 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Journal of Hypertension 2007 25 6 1105 1187 (Pubitemid 46924065)
163. Jafar T. H., Stark P. C., Schmid C. H., Landa M., Maschio G., De Jong P. E., De Zeeuw D., Shahinfar S., Toto R., Levey A. S., Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Annals of Internal Medicine 2003 139 4 244 252
164. Orchard T. J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., Fowler S., The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial Annals of Internal Medicine 2005 142 8 611 619 (Pubitemid 40529957)
165. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin New England Journal of Medicine 2002 346 6 393 403 (Pubitemid 34437694)
166. Giannini S., Serio M., Galli A., Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity Journal of Endocrinological Investigation 2004 27 10 982 991 (Pubitemid 40124199)
167. Gerstein H. C., Yusuf S., Bosch J., Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 2006 368 1096 1105
168. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes New England Journal of Medicine 2007 356 24 2457 2471 (Pubitemid 46919772)
169. Kurukulasuriya L. R., Sowers J. R., Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors Cardiovascular Diabetology 2010 9, article 45
170. van de Laar F. A., Lucassen P. L. B. J., Akkermans R. P., van de Lisdonk E. H., de Grauw W. J. C., Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose Cochrane Database of Systematic Reviews 2006 4
171. Hanefeld M., Chiasson J. L., Koehler C., Henkel E., Schaper F., Temelkova-Kurktschiev T., Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke 2004 35 5 1073 1078 (Pubitemid 38543520)
172. Chiasson J.-L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial Journal of the American Medical Association 2003 290 4 486 494 (Pubitemid 37430502)
173. Amori R. E., Lau J., Pittas A. G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis Journal of the American Medical Association 2007 298 2 194 206 (Pubitemid 47057766)
174. Bhushan R., Elkind-Hirsch K. E., Bhushan M., Butler W. J., Duncan K., Marrioneaux O., Exenatide use in the management of metabolic syndrome: a retrospective data base study Endocrine Practice 2008 14 8 933 999
175. Bergenstal R., Kim T., Trautmann M., Zhuang D., Okerson T., Taylor K., Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes Circulation 2008 118 S1086
176. Mistry G. C., Maes A. L., Lasseter K. C., Davies M. J., Gottesdiener K. M., Wagner J. A., Herman G. A., Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension Journal of Clinical Pharmacology 2008 48 5 592 598 (Pubitemid 351503521)
177. Derosa G., Maffioli P., Salvadeo S. A. T., Ferrari I., Ragonesi P. D., Querci F., Franzetti I. G., Gadaleta G., Ciccarelli L., Piccinni M. N., D'Angelo A., Cicero A. F. G., Exenatide versus glibenclamide in patients with diabetes Diabetes Technology and Therapeutics 2010 12 3 233 240
178. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapya consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clinical Diabetes 2009 32 1 193 203
179. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 12 352 837 353
180. Pyrl K., Ballantyne C. M., Gumbiner B., Lee M. W., Shah A., Davies M. J., Mitchel Y. B., Pedersen T. R., Kjekshus J., Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 2004 27 7 1735 1740 (Pubitemid 38857452)
181. Deedwania P., Barter P., Carmena R., Fruchart J.-C., Grundy S. M., Haffner S., Kastelein J. J., LaRosa J. C., Schachner H., Shepherd J., Waters D. D., Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 2006 368 9539 919 928 (Pubitemid 44331360)
182. Sandhu S., Wiebe N., Fried L. F., Tonelli M., Statins for improving renal outcomes: a meta-Analysis Journal of the American Society of Nephrology 2006 17 7 2006 2016 (Pubitemid 44036185)
183. Douglas K., O'Malley P. G., Jackson J. L., Meta-analysis: the effect of statins on albuminuria Annals of Internal Medicine 2006 145 2 117 124 (Pubitemid 46780585)
184. Athyros V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., Tziomalos K., Ganotakis E. S., Elisaf M., Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome Nephrology Dialysis Transplantation 2007 22 1 118 127 (Pubitemid 46050336)
185. Ansquer J.-C., Foucher C., Rattier S., Taskinen M.-R., Steiner G., Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) American Journal of Kidney Diseases 2005 45 3 485 493 (Pubitemid 40341327)
186. Kahn R., Buse J., Ferrannini E., Stern M., The metabolic syndrome: time for a critical appraisaljoint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2005 28 9 2289 2304 (Pubitemid 41242486)
187. Stern M. P., Williams K., Gonzlez-Villalpando C., Hunt K. J., Haffner S. M., Does the metabolic-syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004 27 11 2676 2681 (Pubitemid 39441469)